Liraglutide in a real-world setting: Joint modeling of metabolic response, prediction of efficacy, and cardiovascular risk

The worldwide prevalence of type 2 diabetes mellitus increases in parallel to that of obesity. Liraglutide (LRG), a glucagon-like peptide-1 receptor agonist, can reduce body weight. This study assessed the metabolic efficacy of LRG in real-world clinical practice. An observational, retrospective coh...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Endocrinologia, diabetes y nutricion Ročník 66; číslo 6; s. 376
Hlavní autori:	Alonso-Troncoso, Isabel, Carollo-Limeres, Carmen, Rios-Prego, Mónica, Guler, Ipek, Cadarso-Suárez, Carmen, F-Mariño, Alexis
Médium:	Journal Article
Jazyk:	English Spanish
Vydavateľské údaje:	Spain 01.06.2019
Predmet:	Aged Cardiovascular Diseases - epidemiology Cardiovascular Diseases - etiology Cardiovascular Diseases - prevention & control Cohort Studies Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Female Forecasting Humans Hypoglycemic Agents - therapeutic use Liraglutide - therapeutic use Male Middle Aged Retrospective Studies Risk Factors Treatment Outcome Estudios en vida real Liraglutida Cardiovascular risk Diabetes mellitus tipo 2 Riesgo cardiovascular Real-world studies Efficacy Type 2 diabetes mellitus Liraglutide Eficacia
ISSN:	2530-0180, 2530-0172, 2530-0180
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	The worldwide prevalence of type 2 diabetes mellitus increases in parallel to that of obesity. Liraglutide (LRG), a glucagon-like peptide-1 receptor agonist, can reduce body weight. This study assessed the metabolic efficacy of LRG in real-world clinical practice. An observational, retrospective cohort study including patients treated with LRG for at least one year (187 patients). Anthropometric and metabolic variables, a composite endpoint, factors predicting response to LRG, and cardiovascular risk over time were assessed. A linear mixed-effects model with a bivariate structure was constructed to investigate the time-dependent relationship between weight and HbA1c values. HbA1c levels and weight significantly decreased in the first 12 weeks, and the decrease persisted at 12 and 24 months in all subgroups studied. Mean weight and HbA1c decreases after 24 months were 8.5kg and 1.7% respectively. HbA1c values <7% were achieved by 42% of patients at 12 months and by 40% at 24 months. Treatment with LRG allowed for reduction in insulin dose. No serious adverse events were noted. Cardiovascular risk decreased from high to moderate-low. Under standard clinical practice conditions, LRG achieved a better metabolic response than seen in clinical trials. Efficacy at 12 weeks of treatment is a good predictor of response. LRG allows for delaying or reducing insulin dose by improving both weight and glucose control. Cardiovascular risk improved.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
ISSN:	2530-0180 2530-0172 2530-0180
DOI:	10.1016/j.endinu.2018.09.005